Follow The Filings

BCRX BioCryst Pharmaceuticals

BioCryst Pharmaceuticals earnings company data as of 4:45 AM ET 11/1

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 4 Nov EPS 0.10 — —
Rev $165.7M — —

Insider trades

Open-market buys and sales by BCRX's executives, directors and 10% owners in the last 12 months, from their Form 4s

All BCRX insider trades
  • None no insider bought on the open market
  • $605K sold by 2 insiders outside a trading plan
  • $3.5M sold by 2 insiders under 10b5-1 plans
  1. Amy E McKee Director
    Sale
    $100K 11,180 shares at $8.97 26% of stake
    Traded May 18 Filed May 19
  2. Alane P Barnes Chief Legal Officer
    Planned sale
    $596K 62,500 shares at $9.54 14% of stake
    Traded May 13 Filed May 15
  3. Theresa Heggie Director
    Sale
    $505K 49,933 shares at $10.11 43% of stake
    Traded Mar 20 Filed Mar 24
  4. Alane P Barnes Chief Legal Officer
    Planned sale
    $1.4M 150,000 shares at $9.15 27% of stake
    Traded Mar 16 Filed Mar 18
  5. Alane P Barnes Chief Legal Officer
    Planned sale
    $167K 21,773 shares at $7.65 5.2% of stake
    Traded Dec 22, 2025 Filed Dec 23, 2025
  6. Alane P Barnes Chief Legal Officer
    Planned sale
    $162K 21,210 shares at $7.65 6.3% of stake
    Traded Dec 15, 2025 Filed Dec 16, 2025
  7. Alane P Barnes Chief Legal Officer
    Planned sale
    $1.2M 161,680 shares at $7.21 32% of stake
    Traded Dec 1–3 Filed Dec 3, 2025
  8. Machelle Sanders Director
    Planned sale
    $69K 9,600 shares at $7.14 24% of stake
    Traded Nov 13, 2025 Filed Nov 17, 2025

Also filed in the last 12 months, not counted as buying or selling: 33 stock grants, 8 option exercises, 6 share withholdings for taxes, 3 gifts, and 1 sale back to the company.

SEC filings

Recent issuer filings from EDGAR, 15 shown.

Filed Form Detail Links
SCHEDULE 13G/A —
SCHEDULE 13G —
8-K 2.02,7.01,9.01
10-Q
8-K/A 2.05
8-K 2.05,7.01,9.01
8-K 5.02,5.07,9.01
SCHEDULE 13G —
8-K 2.02,7.01,9.01
10-Q
8-K 7.01,9.01
SCHEDULE 13G —
DEF 14A
DEFA14A
SCHEDULE 13G/A —

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.